3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Multiple Myeloma
7
Recurrence
1
Purpura
1
Prostatic Neoplasms
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Neoplasms
1
Nausea
1
Macroglossia
1
Lymphoma
1
Lymphadenopathy
1
Leukemia, Myeloid, Acute
1
Leukemia
1
Immunoglobulin Light-chain Amyloidosis
1
Hepatomegaly
1
Hematologic Neoplasms
1
Gastrointestinal Hemorrhage
1
Diarrhea
1
Constipation
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Cytarabine
167
fludarabine phosphate
102
Cyclophosphamide
97
Azacitidine
92
Whole-Body Irradiation
78
fludarabine
77
Mycophenolic Acid
71
Busulfan
68
Tacrolimus
59
Peripheral Blood Stem Cell Transplantation
55
Decitabine
55
Granulocyte Colony-Stimulating Factor
49
Filgrastim
44
Daunorubicin
44
Cyclosporine
42
Methotrexate
41
Melphalan
41
Etoposide
41
Clofarabine
41
Idarubicin
39
Mitoxantrone
34
Antilymphocyte Serum
34
venetoclax
32
thymoglobulin
23
Thiotepa
23
Stem Cell Transplantation
21
Injections
16
Gemtuzumab
16
CPX-351
16
Sirolimus
15
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Leukemia, Myeloid, Acute
×
isatuximab
×
Clear all
NCT03860844
2025-09-09
ISAKIDS
Sanofi
Phase 2
Terminated
67 enrolled
25 charts